Stéphanie Catala

1.1k total citations
7 papers, 359 citations indexed

About

Stéphanie Catala is a scholar working on Oncology, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Stéphanie Catala has authored 7 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Cancer Research and 2 papers in Economics and Econometrics. Recurrent topics in Stéphanie Catala's work include HER2/EGFR in Cancer Research (3 papers), Breast Cancer Treatment Studies (3 papers) and Economic and Financial Impacts of Cancer (2 papers). Stéphanie Catala is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Breast Cancer Treatment Studies (3 papers) and Economic and Financial Impacts of Cancer (2 papers). Stéphanie Catala collaborates with scholars based in France, Belgium and United States. Stéphanie Catala's co-authors include M. Rybojad, M. Mokni, Patrice Morel, Alain Lortholary, Andrew Kramar, Christelle Jouannaud, Marc Espié, Daniel Serin, Pierre Kerbrat and Iris Pauporté and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Stéphanie Catala

7 papers receiving 341 citations

Peers

Stéphanie Catala

ONCOL

CR

RNMI

PERIO

PFM

X. Chai United States

Ruby Gupta United States

João Luís Fernandes da Silva Brazil

Kie Kian Ang United States

Narikazu Boku Japan

Frank W. Chen United States

F Feuilhade France

Jeltje Schulten Germany

Heather Lin United States

Daniel U. Riihimaki United States

X. Chai United States

Stéphanie Catala

89 ×0.4

ONCOL

26 ×0.3

CR

98 ×1.0

RNMI

11 ×0.1

PERIO

30 ×0.5

PFM

Citations per year, relative to Stéphanie Catala Stéphanie Catala (= 1×) peers X. Chai

Countries citing papers authored by Stéphanie Catala

Since Specialization

Citations

This map shows the geographic impact of Stéphanie Catala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Catala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Catala more than expected).

Fields of papers citing papers by Stéphanie Catala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Catala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Catala. The network helps show where Stéphanie Catala may publish in the future.

Co-authorship network of co-authors of Stéphanie Catala

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Catala. A scholar is included among the top collaborators of Stéphanie Catala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Catala. Stéphanie Catala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Curtit, Elsa, Jean-Michel Vannetzel, Sophie Roche, et al.. (2019). Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice. The Breast. 44. 39–45. 13 indexed citations

2.

Penault–Llorca, F, Jean‐Christophe Grenier, Marianne Leheurteur, et al.. (2017). Abstract P2-05-10: UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk. Cancer Research. 77(4_Supplement). P2–5. 2 indexed citations

3.

Ganem, G., Éric-Charles Antoine, Chantal Touboul, et al.. (2016). Maintaining professional activity during breast cancer treatment. European Journal of Cancer Care. 25(3). 458–465. 7 indexed citations

4.

Pivot, X., Gilles Romieu, Marc Debled, et al.. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet Oncology. 14(8). 741–748. 211 indexed citations

5.

Ganem, G., H. Naman, Nadine Dohollou, et al.. (2013). Continuing to work while receiving cancer treatment: A financial or a symbolic issue?. Journal of Clinical Oncology. 31(15_suppl). 6603–6603. 1 indexed citations

6.

Pivot, Xavier, Gilles Romieu, Hervé Bonnefoi, et al.. (2012). Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer. Annals of Oncology. 23. ixe2–ixe2. 13 indexed citations

7.

Mokni, M., et al.. (1991). Lichen planus and hepatitis C virus. Journal of the American Academy of Dermatology. 24(5). 792–792. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact